Meeting
2020 Genitourinary Cancers Symposium
Is body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial.
Authors
Emeline Colomba
Institut Gustave Roussy, Villejuif, France
Emeline Colomba , Cécile Dalban , Aude Flechon , Christine Chevreau , Gwenaelle Gravis , Constance Thibault , Brigitte Laguerre , Philippe Barthelemy , Delphine Borchiellini , Marine Gross Goupil , Lionnel Geoffrois , Frederic Rolland , Antoine Thiery-Vuillemin , Florence Joly , Sylvain Ladoire , Florence Tantot , Bernard Escudier , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 630)
Abstract #
630
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.
First Author: Emeline Colomba
First Author: Carolina Alves Costa Silva
Poster
2023 ASCO Genitourinary Cancers Symposium
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
First Author: Sally Leong
Poster
2022 ASCO Annual Meeting
The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.
First Author: Sara Elena Rebuzzi